From endothelial dysfunction to vascular occlusion: Role of the renin-angiotensin system;Da disfunçao endotelial à oclusão vascular papel do sistema renina-angiotensina

Revista Portuguesa de Cardiologia

Volumn 29, Issue 5, 2010, Pages 801-824

  Marques Da Silva, Pedro ^a  

^a HOSPITAL DE SANTA MARTA   (Portugal)

Author keywords

Atherosclerosis; Endothelial dysfunction; Inflammation; Oxidative stress; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; FOCAL ADHESION KINASE; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PAXILLIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PRORENIN RECEPTOR; PROTEIN C FOS; PROTEIN C JUN; PROTEIN SHC; RAS PROTEIN; RHO FACTOR; SOS PROTEIN; STAT1 PROTEIN; TENSIN; TISSUE PLASMINOGEN ACTIVATOR; TYROSINE; VON WILLEBRAND FACTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR;

ALLELE; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE VARIABILITY; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR RISK; CHROMATIN; CLINICAL ASSESSMENT; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE DELETION; GENE INSERTION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HYPERTENSION; KIDNEY DISEASE; MACROPHAGE; MITOCHONDRION; ONCOGENE C FOS; ONCOGENE C JUN; ONCOGENE C MYC; PATHOPHYSIOLOGY; PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; THROMBOGENESIS; THROMBOGENICITY; BLOOD CLOTTING; CARDIOVASCULAR DISEASES; FIBRINOLYSIS; HUMAN; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; APOPTOSIS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; FIBRINOLYSIS; HUMANS; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 77955979223     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Jeunemaitre X. Genetics of the human renin angiotensin system. J Mol Med 2008; 86: 637-41
2. Corvol P, Jeunemaitre X, Charru A, Soubrier F. The renin-angiotensin system in human hypertension. In: Haber E (ed.). Molecular Cardiovascular Medicine. New York: Scientific American, 1995 : 259-74
3. O'Malley JP, Maslen CL, Illingworth DR. Angiotensin-Converting enzyme and cardiovascular disease risk. Curr Opin Lipidol 1999; 10: 407-15
4. Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease. From genes to treatment. Arch Intern Med 2003; 163: 1155-64
5. Farmer JA, Torre-Amione G. The renin angiotensin system as a risk factor for coronary artery disease. Curr Atheroscl Rep 2001; 3: 117-24
6. Henrion D, Benessiano J, Iglarz M, Philip I, Levy BI. Genetic determinants of vascular reactivity. Curr Hypertens Rep 2002; 4: 41-8
7. Mendonça MI, Marques da Silva P, Brehm A, Freitas AI, Freitas S, Sousa AC et al. Polimorfismos do gene da ECA e risco de doença coronária numa população portuguesa. Rev Port Cardiol 2004; 23: 1593-601
8. Mendonça MI, Brehm A, Marques da Silva P, Freitas AI, Freitas S, Sousa AC et al. Polimorfismos do gene da ECA está associado com a gravidade e a extensão da doença coronária. Rev Port Cardiol 2004; 23: 1695-11
9. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regulatory Peptides 2000; 93: 65-77
10. Re RN. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nature Clin Practice Cardiovasc Med 2004; 1: 42-7
11. Bader M, Ganten D. Update on tissue renin-angiotensin systems. J Mol Med 2008; 86; 86: 615-21
12. Nguyen G, Contrepas A. The (pro)renin receptors. J Mol Med 2008; 86: 643-6
13. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Cir Res 1998; 83: 1182-91
14. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72
15. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-33
16. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52: 639-72
17. Wesselman JPM, De Mey JGR. Angiotensin and cytoskeletal proteins: role in vascular remodeling. Curr Hypertens Rep 2002; 4: 63-70
18. Saito Y, Berk BC. Angiotensin II-mediated signal transduction pathways. Curr Hypertens Rep 2002; 4: 167-71
19. Skultetyova D, Filipova S, Riecansky I, Skultety J. The role of angiotensin type 1 receptor in inflammation and endothelial dysfunction. Recent Patents on Cardiovasc Discovery 2007; 2: 23-7
20. Wolf G. Free radical production and angiotensin. Curr Hypertens Rep 2000; 2: 167-73
21. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501
22. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. Circ Res 2000; 86: 840-44
23. Van Heerebeek L, Meischl C, Stooker W, Meijer CJLM, Niessen HWM, Roos D. NADPH oxidase(s). New source(s) of reactive oxygen species in the vascular system? J Clin Pathol 2002; 55: 561-8
24. Lassègue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Regul Integr Comp Physiol 2003; 285: 277-97
25. Raij L. Hypertension and cardiovascular risk factors. Role of the angiotensin II-nitric oxide interaction. Hypertension 2001; 37 (part 2): 767-73
26. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends in Pharmacol Sciences 2008; 29: 367-74
27. Strawn WB, Ferrario CM. Mechanisms linking angiotensin II and atherogenesis. Curr Opin Lipidol 2002; 13: 505-12
28. Brasier AR, Recinos III A, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257-66
29. Delafontaine P. Growth factors and vascular smooth muscle cell growth responses. Eur Heart J 1998;19 (suppl G): G18-22
30. Phillips MI, Kagiyama S. Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs 2002; 3: 569-77
31. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-6
32. -tefanec T. Endothelial apoptosis. Could it have a role in the pathogenesis and treatment of disease? Chest 2000; 117: 841-54
33. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 2001; 88: 998-1003
34. Choy JC, Granville DJ, Hunt DWC, McManus BM. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 2001; 33: 1673-90
35. Napoli C. Oxidation of LDL, atherogenesis, and apoptosis. Ann NY Acad Sci 2003; 1010: 698-709
36. Ruiz-Ortega M, Ruperez M, Esteban V, Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 2003; 5: 73-9
37. Ferrario CM, Smith R, Levy P, Strawn W. The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. Am J Med Sci 2002; 323: 17-24
38. Singh BM, Mehta JL. Interactions between the renin-angiotensin system and dyslipidemia. Relevance in the therapy of hypertension and coronary heart disease. Arch Intern Med 2003; 163: 1296-304
39. Itabe H. Oxidized low-density lipoproteins: what is understood and what remains to be clarified. Biol Pharm Bull 2003; 26: 1-9
40. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Mon 2005; 11: RA194-205
41. Ferrario CM, Strawn WB. Targeting the RAAS for the treatment of atherosclerosis. Drug Discovery Today: Therapeutic Strategies 2005; 2: 221-9
42. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98: 121-8
43. Mazzolai L, Hayoz D. The renin-angiotensin system and atherosclerosis. Curr Hypertens Rep 2006; 8: 47-53
44. Montecucco F, Pende A, Mach F. The renin-angiotensin System modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators of Inflammation 2009; doi:10.1155/2009/752406
45. Stocker R, Keaney Jr JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-478
46. Ferrario CM, Richmond RS, Smith R, Levy P, Strawn WB, Kivlighn S. Renin-angiotensin system as a therapeutic target in managing atherosclerosis. Am J Therap 2004; 11: 44-53
47. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Rupérez M, Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001; 10: 321-9
48. Fuster V, Corti R. Evolving concepts of atherothrombosis. In: Fuster V (ed). Assessing and Modifying the Vulnerable Atherosclerotic Plaque. Armonk, NY: Futura Publishing, Inc.; 2002: 1-27
49. Ott I. Tissue factor in acute coronary syndromes. Semin Vasc Med 2003; 3: 185-92
50. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24: 1015-22
51. Vaughan DE. Angiotensin, fibrinolysis, and vascular homeostasis. Am J Cardiol 2001; 87 (suppl): 18C-24C
52. Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, Mihaly J, Prager GW. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 2002; 17: 56-61
53. Vaughan DE. Angiotensin and vascular fibrinolytic balance. Am J Hypertens 2002; 15: 3S-8S
54. Fay WP. Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury. Trends Cardiovasc Med 2004; 14: 196-202
55. Chai SY, Fernando R, Peck G, Ye SY, Mendelsohn FA, Jenkins TA, Albiston AL. The angiotensin IV/AT4 receptor. Cell Mol Life Sci 2004; 61: 2728-37
56. Ruiz-Ortega M, Lorenzo O, Rupérez M, Esteban V, Suzuki Y, Mezzanno S, Plaza JJ, Egido J. Role of the renin-angiotensin system in vascular diseases. Expanding the field. Hypertension 2001; 38: 1382-7
57. Struthers AD. Effect of aldosterone on the vascular bed: introducing the aldosterone-induced vasculopathy. In: Braunwald E (ed.): Harrison's Advances in Cardiology. New York: McGraw Hill, 2003: 12-7
58. Neves MF, Schiffrin EL. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep 2003; 5: 59-65